These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway. Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520 [TBL] [Abstract][Full Text] [Related]
10. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Hoy SM Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266 [TBL] [Abstract][Full Text] [Related]
13. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
15. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells. Kim JH; Lee SJ; Kang KW; Lee BH; Park Y; Kim BS Biochem Pharmacol; 2021 Aug; 190():114658. PubMed ID: 34146540 [TBL] [Abstract][Full Text] [Related]
16. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review. Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712 [TBL] [Abstract][Full Text] [Related]
17. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052 [TBL] [Abstract][Full Text] [Related]
18. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150 [TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). Wu J; Wang A; Li X; Chen C; Qi Z; Hu C; Wang W; Wu H; Huang T; Zhao M; Wang W; Hu Z; Liu Q; Wang B; Wang L; Li L; Ge J; Ren T; Xia R; Liu J; Liu Q Cancer Biol Ther; 2019; 20(6):877-885. PubMed ID: 30894066 [TBL] [Abstract][Full Text] [Related]
20. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Wongboonma W; Thongnoppakhun W; Auewarakul CU Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]